Zacks Investment Research upgraded shares of Cesca Therapeutics (NASDAQ:KOOL) from a hold rating to a buy rating in a research note published on Tuesday, reports. Zacks Investment Research currently has $3.25 target price on the biotechnology company’s stock.

According to Zacks, “Cesca Therapeutics Inc. is engaged in the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine. It also develops and manufactures automated blood and bone marrow processing systems and companion disposable products that enable the separation, processing and preservation of cell and tissue therapy products. The Company sells its products in approximately 30 countries throughout the world to customers that include private and public cord blood banks, surgeons, hospitals and research institutions. Cesca Therapeutics Inc., formerly known as ThermoGenesis Corp., is headquartered in Rancho Cordova, California. “

A number of other research analysts have also recently issued reports on the stock. ValuEngine raised shares of Cesca Therapeutics from a hold rating to a buy rating in a report on Tuesday, July 2nd. HC Wainwright reaffirmed a buy rating and issued a $6.50 target price (up from $1.00) on shares of Cesca Therapeutics in a report on Wednesday, August 14th.

Shares of Cesca Therapeutics stock opened at $3.06 on Tuesday. Cesca Therapeutics has a 12-month low of $2.10 and a 12-month high of $5.25. The company has a quick ratio of 0.91, a current ratio of 1.52 and a debt-to-equity ratio of 0.50. The company has a 50-day moving average of $3.11 and a two-hundred day moving average of $1.39.

Cesca Therapeutics (NASDAQ:KOOL) last issued its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.47) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.60) by $0.13. Cesca Therapeutics had a negative net margin of 98.84% and a negative return on equity of 77.30%. The company had revenue of $4.31 million during the quarter, compared to analysts’ expectations of $3.40 million. As a group, equities research analysts forecast that Cesca Therapeutics will post -0.45 earnings per share for the current year.

About Cesca Therapeutics

Cesca Therapeutics Inc develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products.

Read More: Why do corrections happen?

Get a free copy of the Zacks research report on Cesca Therapeutics (KOOL)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Cesca Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cesca Therapeutics and related companies with's FREE daily email newsletter.